Background: Sarcomatoid differentiation/histology of renal cell carcinoma (sRCC) in patients with metastatic renal cell carcinoma (mRCC) is still underresearched in current therapy regimes. We aimed to evaluate the impact of sRCC on outcomes in patients with mRCC treated with tyrosine kinase inhibitors (TKIs). Methods: We collected complete data of 262 consecutive mRCC patients from our institutional database for this retrospective study. All patients were treated with TKIs within a single or multimodal treatment approach. All analyses were adjusted for the presence of sRCC. Descriptive statistics as well as uni- and multivariable outcome metrics, including progression-free (PFS) and overall survival (OS) as endpoints were performed. Results: Overall, 18 patients had sRCC (6.9%). Patients with sRCC had more often clear-cell histology (p = 0.047), a higher T-stage (p = 0.048), and underwent cytoreductive nephrectomy more frequently (p < 0.001). The most common first-line TKIs were Sunitinib (65.6%), Sorafenib (19.5%), and Pazopanib (10.3%), respectively. At a median follow-up of 32 months, patients with sRCC had significantly reduced PFS (p = 0.02) and OS (p = 0.01) compared to patients without sRCC. In multivariable analyses that adjusted for the effects of standard mRCC predictors, the sarcomatoid feature retained its independent association with inferior PFS (HR: 2.39; p = 0.007) and OS (HR: 2.37; p = 0.001). This association remained statistically significant in subgroup analyses of patients with Sunitinib as first-line therapy (PFS p < 0.001; OS: p < 0.001). Conclusion: Despite its rare occurrence, our findings confirm sRCC as a powerful predictor for inferior outcomes in mRCC treated with targeted therapies. This suggests a need for more tailored treatment strategies in patients harboring mRCC with sarcomatoid histology to improve oncological outcomes.

Department of Pathology Medical University of Hamburg Hamburg Germany

Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia

Department of Urology and Andrology Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Department of Urology Medical University of Hamburg Hamburg Germany

Department of Urology Medical University of Vienna Vienna Austria

Department of Urology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan

Department of Urology Shariati Hospital Tehran University of Medical Sciences Tehran Iran

Department of Urology University of Texas Southwestern Medical Center Dallas TX United States

Department of Urology Weill Cornell Medical School New York NY United States

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Zobrazit více v PubMed

Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, et al. . Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: results from the international metastatic renal cell cancer database consortium (IMDC). Kidney Cancer. (2017) 1:41–7. 10.3233/KCA-160002 PubMed DOI PMC

Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, et al. . Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med. (2017) 6:902–9. 10.1002/cam4.1048 PubMed DOI PMC

Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, et al. . Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer. (2015) 13:e79–85. 10.1016/j.clgc.2014.08.011 PubMed DOI

Naher S, Padinharakam S, Balakrishnar B, Chua W, Descallar J, Adams D, et al. . Patterns of presentation and treatment outcomes of non-clear-cell renal cell carcinoma and sarcomatoid renal cell carcinoma patients in 2 tertiary referral centers in Sydney, Australia. Clin Genitourin Cancer. (2019) 17:e565–e9. 10.1016/j.clgc.2019.02.006 PubMed DOI

Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, et al. . Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. (2004) 28:435–41. 10.1097/00000478-200404000-00002 PubMed DOI

Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, et al. . Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. (2015) 67:85–97. 10.1016/j.eururo.2014.04.029 PubMed DOI

Ito T, Pei J, Dulaimi E, Menges C, Abbosh PH, Smaldone MC, et al. . Genomic copy number alterations in renal cell carcinoma with sarcomatoid features. J Urol. (2016) 195:852–8. 10.1016/j.juro.2015.10.180 PubMed DOI PMC

Jones TD, Eble JN, Wang M, Maclennan GT, Jain S, Cheng L. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer. (2005) 104:1195–203. 10.1002/cncr.21288 PubMed DOI

Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer CP, Klotzbücher T, et al. . The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. Urol Oncol. (2020) 38:739.e9–.e15. 10.1016/j.urolonc.2020.04.033 PubMed DOI

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. (2000) 92:205–16. 10.1093/jnci/92.3.205 PubMed DOI

Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, et al. . Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. (2015) 121:3435–43. 10.1002/cncr.29503 PubMed DOI

Beuselinck B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, et al. . Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. Clin Genitourin Cancer. (2014) 12:e205–14. 10.1016/j.clgc.2014.04.004 PubMed DOI

Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, et al. . A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. (2015) 115:405–11. 10.1111/bju.12781 PubMed DOI

Yan Y, Liu L, Zhou J, Li L, Li Y, Chen M, et al. . Clinicopathologic characteristics and prognostic factors of sarcomatoid renal cell carcinoma. J Cancer Res Clin Oncol. (2015) 141:345–52. 10.1007/s00432-014-1740-1 PubMed DOI PMC

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, et al. . Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. (2009) 27:235–41. 10.1200/JCO.2008.18.0000 PubMed DOI

Zhi H, Feng M, Liu S, Na T, Zhang N, BiLiGe W. Prognostic significance of sarcomatoid differentiation in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. Front Oncol. (2020) 10:591001. 10.3389/fonc.2020.591001 PubMed DOI PMC

Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. (2017) 376:354–66. 10.1056/NEJMra1601333 PubMed DOI

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. (2015) 373:1803–13. 10.1056/NEJMoa1510665 PubMed DOI PMC

McDermott DF, Choueiri TK, Motzer RJ, Aren OR, George S, Powles T. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J Clin Oncol. (2019) 37:4513. 10.1200/JCO.2019.37.15_suppl.4513 PubMed DOI

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. . Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. (2016) 17:917–27. 10.1016/S1470-2045(16)30107-3 PubMed DOI

Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, et al. . Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clin Cancer Res. (2017) 23:6686–96. 10.1158/1078-0432.CCR-17-1057 PubMed DOI PMC

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, et al. . Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci USA. (2016) 113:2170–5. 10.1073/pnas.1525735113 PubMed DOI PMC

Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. (2016) 17:e542–e51. 10.1016/S1470-2045(16)30406-5 PubMed DOI PMC

Shin SJ, Jeon YK, Cho YM, Lee JL, Chung DH, Park JY, et al. . The association between PD-L1 expression and the clinical outcomes to vascular endothelial growth factor-targeted therapy in patients with metastatic clear cell renal cell carcinoma. Oncologist. (2015) 20:1253–60. 10.1634/theoncologist.2015-0151 PubMed DOI PMC

Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, et al. . Survival outcomes and tumor IMP3 expression in patients with sarcomatoid metastatic renal cell carcinoma. J Oncol. (2015) 2015:181926. 10.1155/2015/181926 PubMed DOI PMC

Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, et al. . Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer. (2010) 116:616–24. 10.1002/cncr.24768 PubMed DOI PMC

Shuch B, Said J, Rochelle JCL, Zhou Y, Li G, Klatte T, et al. . Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology–is up-front resection indicated and, if not, is it avoidable? J Urol. (2009) 182:2164–71. 10.1016/j.juro.2009.07.049 PubMed DOI PMC

Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, et al. . Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer. (2019) 17:e678–e88. 10.1016/j.clgc.2019.03.018 PubMed DOI PMC

Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. . Sunitinib Alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. (2018) 379:417–27. 10.1056/NEJMoa1803675 PubMed DOI

Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid renal cell carcinoma: population-based study of 879 patients. Clin Genitourin Cancer. (2019) 17:e447–e53. 10.1016/j.clgc.2019.01.005 PubMed DOI

Ji B, Li D, Fu S, Zhang Z, Yang T, Wu Y, et al. . A population study to identify candidates for cytoreductive nephrectomy in patients with metastatic sarcomatoid renal cell carcinoma from the surveillance, epidemiology, and end results (SEER) database. Med Sci Monit. (2020) 26:e921297. 10.12659/MSM.921297 PubMed DOI PMC

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors